Business
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
CORAL GABLES, Fla., May 11, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the
About this update from Relmada Therapeutics, Inc.
[{"type":"text","content":"CORAL GABLES, Fla., May 11, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the first quarter ended March 31, 2023. The Company will host a conference call today, Thursday, May 11, at 4:30 PM Eastern Time/1:30 PM Pacific Time.\n\n \n \n \n \n \n \n\n \n\"We are focused on optimizing the potential for success in the promising late-stage development program of REL-1017 for the adjunctive treatment of major depressive disorder,\" said Sergio Traversa, Relmada's Chief Executive Officer. \"The amended protocol for ongoing Study 302, is now being implemented and enrollment is progressing, with trial completion anticipated in the first half of 2024. For the new planned Study 304, we have finalized site selection and solidified a rigorous patient eligibility process.\"\n\"We are optimistic about the protocol and trial design improvements we have made. Based on data generated to date, we believe we have been able to identify those clinical sites that were better able to control placebo response, and those that understand the importance of enrolling appropriate subjects with documented diagnoses and treatment histories. We have increased our own internal oversight of the subject eligibility process with the build-out of an internal clinical development team led by our Chief Medical Officer, Dr. Cedric O'Gorman, who has previously run positive registrational trials in MDD. Moreover, we are sufficiently funded to execute our plans to reach data readouts from both Phase 3 trials in 2024.\"\nRecent Corporate Highlights Implemented the amended protocol for ongoing Reliance II (Study 302), a Phase 3 trial of REL-1017 for the adjunctive treatment of MDD Completed protocol and finalized site selection for Study 304, the new planned Phase 3 trial of REL-1017 for the adjunctive treatment of MDD Conclusion of Reliance OLS (Study 310), a long-term, open-label study of REL-1017 in MDD Two late-breaking posters accepted for presentation at the upcoming 2023 American Society of Clinical Psychopharmacology Meeting Upcoming Anticipated Milestones for REL-1017Complete enrollment in ongoing Reliance II (Study 302), which is planned to enroll approximately 3...